Re-Dosing With Gene Therapies in Rare DiseasesByTakashi Kei Kishimoto, PhD,Carsten Brunn, PhDJune 15th 2022Takashi Kei Kishimoto, PhD, and Carsten Brunn, PhD, the chief science and executive officers of Selecta Biosciences, discussed the immunogenicity-mitigating properties of ImmTOR.